Strasbourg, November 7, 2019 – HypnoVR, a French startup specializing in the development of virtual reality medical hypnosis solutions, and the Vivalto Santé Group, France’s third largest player in private hospital care, have announced the signing of a major agreement covering three areas: distribution of HypnoVR’s software, clinical research, and codevelopment.
Formalized through the signing of a framework agreement, the partnership aims to facilitate the adoption of the innovative solution developed by HypnoVR within all of the Vivalto Santé Group’s health facilities. Together, HypnoVR and the Vivalto Santé Group hope to ensure that as many patients as possible across Vivalto Santé’s 32 hospitals can benefit from the device, which reduces pain, stress and anxiety. The agreement also covers setting up clinical trials for a variety of indications and codeveloping upgrades to HypnoVR’s software, in collaboration with the Vivalto Santé Group’s teams.
HypnoVR is a medical device with clinically proven effectiveness designed by two anesthesiologists and hypnotherapists. HypnoVR induces an altered state of consciousness in the patient and maintains this state for the duration of a medical procedure, meaning general anesthetic can be replaced with local anesthetic combined with the virtual reality headset. Alternatively, it can be used to support local and regional anesthesia. Used in numerous types of surgery, HypnoVR offers an effective alternative with none of the side effects associated with traditional chemical anesthesia.
HypnoVR software is also used as an anxiolytic in place of premedication to deeply relax the patient before a stressful medical procedure, as well as for analgesia as an adjunct to morphine in postoperative pain management.
These multiple applications open up the scope of research to other medical specialties. Several research programs are currently underway within the Vivalto Santé Group to confirm the promising results already obtained from clinical trials through prospective, randomized studies.
The partnership agreed with HypnoVR reflects the Vivalto Santé Group’s innovation strategy, which aims to get doctors working within the Group involved in developing partnerships and the Group to engage in co-creation with the health startups of tomorrow. Convinced that the technology could improve the patient experience (with use of anxiolytics and opioids down by half, and side effects reduced) and optimize hospital practice (through better working conditions for practitioners), Daniel Caille, CEO of the Vivalto Santé Group, was among the first to back the Alsace-based startup: “Innovation has always been a priority within the Vivalto Santé Group, and this move to make HypnoVR technology available to our patients and teams enhances that commitment. This partnership is a concrete illustration of our desire to support our doctors in the development of their practice and to improve care for all our patients.”
Three years after the company was founded, and following significant development work with health facilities, this agreement constitutes a major step forward for HypnoVR. Nicolas Schaettel, co-founder and president of HypnoVR, said: “We are happy and proud to have been chosen by the Vivalto Santé Group. In particular, this partnership will enable us to quickly spread the word about the benefits of medical hypnosis via HypnoVR. One of HypnoVR’s core missions is to make the proven benefits of medical hypnosis for reducing pain and anxiety accessible to as many people as possible. This collaboration with the Vivalto Santé Group is a key step for us in that sense.”
HypnoVR is a company specializing in the development of medical hypnosis combined with virtual reality for anesthesia and to treat pain, stress, and anxiety. HypnoVR designs, develops, and markets software applications and medical devices that together form groundbreaking hypnosedation tools that make the benefits of medical hypnosis accessible to as many people as possible.
About the Vivalto Santé Group
Founded in 2009 by Daniel Caille, and now comprising a network of 32 health facilities located in Brittany, Normandy, Île-de-France, Auvergne-Rhône-Alpes, Pays de la Loire and Nouvelle-Aquitaine, the Vivalto Santé Group is now the third largest private hospital group in France, with a turnover of over €600 million.
The Vivalto Santé Group aims to develop cross-facility medical projects to consolidate its centers of excellence and boost medical expertise within each facility. Its network of facilities therefore boasts strong regional coverage, enabling it to meet the expectations of all healthcare professionals and patients.
Tel.: +33 (0)6 09 36 05 97
Tel.: +33 (0)6 88 79 74 66
Vivalto Santé contacts
Group Marketing & Communications Director
Tel.: +33 (0)6 72 93 31 78
For more information, visit www.vivalto-sante.com and follow us on Twitter, LinkedIn, Facebook, & YouTube